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A bone-derived rat cell line, PyMS, releases IGF I and IGF carrier proteins which are similar to those found in rat serum. 
Western blot analysis of culture media conditioned by hormone-treated cells shows that growth hormone and IGF I 
stimulate and cortisol inhibits production of IGF carrier proteins in vitro. A glycosylated carrier protein species of 49-42 
kDa is closely related to the subunits of the growth hormone-dependent carrier protein complex found in rat serum. 
In addition, rhIGF I rapidly induces a 32 kDa, non-glycosylated IGF-binding protein whose accumulation is markedly 
increased by cortisol. 
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1. INTRODUCTION 
Insulin-like growth factors (IGFs) are structural 
homologues of insulin affecting growth and dif- 
ferentiation of connective tissue cells both in vivo 
and in vitro [l]. In serum and other extracellular 
spaces of the mammalian organism, IGFs are 
bound to specific carrier proteins [2,3]. The 
predominant species of carrier protein found in 
native rat serum is a complex of 150-200 kDa (by 
neutral gel filtration on Sephadex G-200) con- 
sisting of glycosylated subunits with apparent 
molecular masses of 42-49 kDa (by gel elec- 
trophoresis) 131. While amino-terminal amino acid 
and cDNA sequences of some IGF carrier protein 
species have recently been reported [4-71, their 
physiological roles remain a matter of speculation. 
Observations that target cells for IGFs, including 
fibroblasts [8,9] and bone cells [lo], produce IGF 
carrier proteins in vitro suggest that they may 
regulate the local bioavailability of IGFs. To this 
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end, it appears essential that carrier protein release 
be well controlled. Therefore, we have studied IGF 
carrier protein production in a bone-derived rat 
cell line, PyMS, under the influence of three hor- 
mones: IGF I, growth hormone, and cortisol. Our 
data show that carrier protein release by 
osteoblastic cells into the culture medium is under 
endocrine control. 
2. MATERIALS AND METHODS 
2.1. Cell cultures 
PyMS cells [ll] were a generous gift from Dr A. Lichtler, 
University of Connecticut. This bone-derived cell line was used 
for the present study since it had been previously found to res- 
pond to IGF I and cortisol in a manner comparable to 
osteoblast-like calvaria cells in primary culture (regarding 
glycogen, collagen and DNA synthesis). PyMS cells were grown 
in Falcon dishes (10 cm diameter) to confluence in Ham’s F12 
medium containing 2 mM glutamine and 1% FCS (all from 
Gibco), then rinsed with protein-free medium and exposed to 
test medium as indicated. In order to minimize interference of 
added IGF carrier proteins, care was taken when supplementing 
the medium with proteins: it contained either serum from 
hypophysectomized rats at 0.1% or charcoal-treated bovine 
serum albumin (BSA, from Serva) at 1 g/l. Hydrocortisone and 
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tunicamycin were from Sigma, recombinant human growth 
hormone from Nordisk and recombinant human (rh) IGF I 
from Ciba-Geigy. After incubating the confluent monolayers at 
37°C in a humidified atmosphere gassed with a mixture of air 
and CO2 (19: l), the medium was removed and saved for carrier 
protein analysis. 
2.2. Medium processing 
Comparison of conditioned media with control media 
without cells allows determination of net IGF carrier protein 
output by cells in vitro. The collected media were dialyzed 
against 0.1 M ammonium acetate, lyophilized, and dissolved in 
200 ~1 distilled water for Western blots and radioimmunoassay. 
2.3. Western blots of carrier proteins 
IGF carrier proteins were identified according to Hossenlopp 
et al. [2] as described elsewhere [5]. In brief, aliquots of 10 ~1 
were electrophoresed on 15% SDS-polyacrylamide gels under 
non-reducing conditions (except he “‘C-labeled molecular mass 
marker: Rainbow marker, Amersham, England) and transfer- 
red to nitrocellulose. The air-dried filters were washed in Tris- 
buffered saline (TBS; 0.15 M NaCI, 10 mM Tris, pH 7.4) con- 
taining 0.1% Tween 20, then incubated with ‘*‘I-labeled IGF II 
(4 x lo6 cpm per plastic bag) for 6 h at room temperature. 
After washing with TBS containing 0.1% Tween 20 the filters 
were exposed for l-2 days at - 80°C to an X-ray film (Kodak 
X-OMAT AR) in cassettes equipped with intensifying screens. 
2.4. Digestion of samples with N-glycanase 
Aliquots of medium samples were incubated in the presence 
of N-glycanase (Genzyme Corporation, Boston, MA) as 
described elsewhere [5], electrophoresed and transblotted as 
above. 
2.5. IGF I radioimmunoassay 
irIGF I was determined [3] using a rabbit antiserum against 
human IGF I with human IGF I as a standard. Sample aliquots 
were acid-treated and run on Sep-Pak Cts cartridges. They were 
assayed at 3 different dilutions. 
2.6. Dot hybridization analysis for type I procollagen mRNA 
After washing with cold PBS, total RNA was prepared after 
extractions with phenol/chloroform and guanidine hydrochlo- 
ride, dotted in serial dilutions onto nitrocellulose and hybri- 
dized to a nick-translated cDNA specific for the LYE chain of 
type 1 procollagen as described elsewhere (121. Hybridization 
signals reflect steady-state l vels of mRNA encoding the ml(I) 
chain of type I procollagen (per amount of total RNA). 
2.7. Cell number and alkaline phosphatase activity 
Cells were grown on 35 mm dishes to confluence in Ham’s 
F12 medium supplemented with 1% FCS, then exposed to test 
medium (BSA at 1 g/l) containing the hormones. 4 days later, 
monolayers were washed with PBS. For the determination of 
cell number, cells were detached from the dishes with trypsin- 
EDTA and counted in a hemocytometer. For the determination 
of alkaline phosphatase activity, cells were lysed into 2 ml of 
0.1% Triton X-100 and enzyme activity was assayed in aliquots 
of cell lysates as in [13] by measuring the cleavage of p- 
nitrophenyl phosphate to p-nitrophenol at pH 10.2. 
3. RESULTS AND DISCUSSION 
The rat bone-derived cell line, PyMS [ 111, was 
found to release specific IGF-binding proteins into 
the culture medium. The major species produced 
by the cells was undistinguishable from the 
subunits of the large molecular mass carrier pro- 
tein complex in rat serum [3] (fig.1): iz51-IGF II 
detects mainly bands of apparent molecular masses 
49/45/42 kDa (‘triplet’). The carrier protein 
species appearing as triplet is more abundant in 
medium from cells which had been exposed to 
growth hormone (fig.1). A similar degree of 
stimulation by growth hormone with a maximum 
at 1 nM was found in experiments where the test 
medium contained 1 g/l BSA instead of 0.1% 
serum from hypophysectomized rats. N-Glycanase 
treatment of medium samples reduced the size of 
the 49/45/42 kDa bands to yield a single band of 
37 kDa (fig.1). Thus, this carrier protein shares at 
least 4 properties with the subunits which belong to 
the 200 kDa carrier protein complex, which is the 
most abundant form in rat serum: IGF binding, 
molecular size, glycosylation, and growth hor- 
mone dependence. However, the amino acid se- 
quence of the protein produced by the cells has not 
yet been determined, whereas the amino acid se- 
quence of the N-term of proteins from rat serum 
which yield the triplet on Western blot is known 
151. 
Tunicamycin, which inhibits glycosylation, com- 
pletely prevented (at 1 pg/ml) the release of this 
carrier protein by the cells. Instead, another IGF- 
binding protein was found in the medium, the size 
of which could not be reduced upon treatment with 
N-glycanase. 
An experiment addressing the time course of 
carrier protein release in the absence and in the 
presence of human IGF I (fig.2) shows accumula- 
tion of IGF carrier proteins in the medium, and, in 
addition, a change in pattern. rhIGF I particularly 
stimulates the production of a carrier protein 
migrating at about 32 kDa which cannot be 
digested with N-glycanase (fig.2). 
Additional experiments (not shown) revealed 
that 8 h of IGF I treatment were sufficient to bring 
about an increased signal of the 32 kDa band. This 
protein was not detected in media from control- 
treated and growth hormone-treated cells. Upon 
prolonged incubation times (4 days), this non- 
329 






RS GH GH - GH GH GH GH 
TN - - TN TN - - 
GL - GL - 
Fig. 1. Western blot analysis of IGF carrier proteins in rat serum 
and in culture media conditioned by rat osteoblastic ells during 
4 days. Normal rat serum (RS) and media were analyzed by 
SDS-polyacrylamide gel electrophoresis under non-reducing 
conditions, transfer to nitrocellulose, and incubation of blots 
with ‘*‘I-IGF II for detection of IGF carrier proteins by 
autoradiography as described in section 2. Cells were exposed 
for 4 days to MEM/FlZ (1: 1) medium containing 0.1% serum 
from hypophysectomized rats. Growth hormone (GH) at 1 nM 
and tunicamycin (TN) at 1 /g/ml were added as indicated. The 
medium samples run on the first 2 lanes were also treated with 
N-glycanase (right, GL). 
glycosylated protein tended to disappear (figs 2,3). 
Exposure of cells (including pretreament schedules 
of 2 days) to cortisol still allowed IGF I to induce 
the 32 kDa band, and, in addition, favored its ac- 
cumulation in medium conditioned during 4 days 
(fig.3). As with short term incubations in the 
absence of cortisol, experiments with a test period 
of 4 days in the presence of cortisol (1 PM) yield a 
dose-dependent s imulation of the 32 kDa band by 
IGF I, IGF II in higher concentrations and insulin. 
The relative potency of the 3 hormones is in keep- 
ing with their affinity for the type 1 IGF receptor. 
Again, this effect is not shared by growth hor- 
mone. Altogether, the data suggest that this non- 
glycosylated 32 kDa IGF carrier protein is 
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Fig.2. Western blot analysis of IGF carrier proteins in culture 
media from rat osteoblastic cells after 1, 2, and 4 days of 
exposure to human IGF I. Cells were exposed to MEM/F12 
(1: 1) medium for 1, 2, and 4 days, as indicated, in the absence 
(control) or in the presence of rhIGF I at 10 nM (IGF I). The 
samples run on lanes 3 and 4 were also treated with N-glycanase 
(right, GL). 
life in vitro. A similar carrier protein was transient- 
ly present in serum from IGF I-treated 
hypophysectomized rats [3]. It remains to be seen 
whether this carrier protein species is related to the 
‘fetal’ carrier protein [4]. 
It took longer incubation times for the 
42-49 kDa carrier proteins (the triplet) to ac- 
cumulate in the medium, and finally, to become 
the predominant form (fig.2). As discussed above, 
CONTROL 
IGF I, 10 nM 
CORTISOL, 1 PM 
CORTISOL + IGF I 
69 46 30 14.3 
kDa 
Fig.3. Western blot analysis of IGF carrier proteins in culture 
media from rat osteoblastic ells exposed for 4 days to cortisol 
and to insulin-like growth factor I. Cells were exposed for 4 
days to F12 medium containing BSA (1 g/l) and hormones, as 
indicated. Conditioned media were processed as described in 
section 2. By the same analysis, IGF carrier proteins were not 
detected in medium which had not been conditioned by cells. 
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this glycosylated species (figs 1,2) corresponds ‘to 
the subunits of the growth hormone-dependent 
large molecular mass carrier complex, the most 
abundant IGF-binding protein in rat serum [3]. 
Similarly to the situation in vivo [3], this carrier 
protein species is found in increased amounts in 
conditioned medium of cells exposed to IGF I (figs 
2,3) or growth hormone (fig.1). 
The appearance of this protein in medium from 
cells which were not stimulated by any hormone 
may be due to endogenously produced IGF I. As 
measured by radioimmunoassay, IGF I ac- 
cumulated in the medium conditioned by cells ex- 
posed to hormone- and protein-free medium 
(experiment shown in fig.2, left): 19 ng human 
RIA equivalents per dish after one, 14.2 ng after 2, 
and 54.7 ng after 4 days of culture. 
The triplet signal was markedly reduced in 
medium from cortisol-treated cells and increased 
in medium from IGF I-treated cells (fig.3). 
Stimulation of triplet production by IGF I was 
dose-dependent (with the steepest part of the dose- 
response curve between 1 and 10 nM), and so was 
the suppression of the signal by cortisol. Cortisol 
inhibits DNA and collagen synthesis, and it 
markedly decreased carrier protein release by 
PyMS cells at relatively low concentrations 
(lo-100 nM) and in a dose-dependent manner. 
Under the conditions used in the experiment of 
fig.3, IGF I increased the relative abundance of 
type I procollagen mRNA and prevented the 
decrease caused by cortisol (table 1); likewise, 
cortisol resulted in decreased alkaline phosphatase 
activity which was prevented in part by IGF I 
(table 1). 
The effects of IGF I and of cortisol on the 
release of glycosylated IGF carrier proteins cor- 
relate with their effects on DNA synthesis and col- 
lagen mRNA levels in the same cells. Reminiscent 
of the situation in vivo, where the abundance of 
the subunits belonging to the large carrier protein 
complex reflects the IGF I status [3], the 
prevalence of the 49/45/42 kDa bands (triplet by 
Western blot) in the culture medium appears to 
correlate also with cell growth in vitro. 
In conclusion, the data show that an osteoblastic 
cell line, PyMS, produces IGF carrier proteins in a 
controlled manner. This particular cell line was 
derived from rat calvarial bone cells by introduc- 
tion of immortalizing DNA sequences, and it has 
Table 1 
RNA yield, ~~(1) procollagen mRNA levels, cell number, and 
alkaline phosphatase activity of rat osteoblastic cells 4 days 
after exposure to hormones 
Medium RNA Collagen Cell Alkaline 
yield mRNA number phos- 
@g/dish) (treated/ (105/dish) phatase 
control) Gmol/dish 
per h) 
Control 35 1.0 7.8 f 0.4 4.4 + 0.2 
IGF I, 10 nM 42 2.4 8.0 + 0.3 5.6 LIZ 0.2 
Cortisol, 1 PM 19 0.3 5.6 f 0.5 2.0 + 0.1 
Cortisol + IGF I 34 1.5 7.4 f 0.3 3.5 f 0.2 
After removal of the medium (experiment as in fig.3) RNA was 
prepared, fixed onto nitrocellulose in equal amounts (2, 1, 
0.5 pg), and hybridized to a nick-translated cDNA specific for 
the cyr chain of type I procollagen. Hybridization signals were 
estimated by liquid scintillation counting of cut filters. Relative 
al(l) collagen mRNA levels are given as ratios 
cpm(treated)/cpm(control) per amount of total RNA dotted. 
To detect hormone effects on cell number and alkaline 
phosphatase activity under the same conditions, PyMS cells 
were grown on 35 mm dishes as described in section 2.7. 
Enzyme activity is expressed asp-nitrophenol released. Data are 
expressed as mean + SE, n = 8, 2 experiments 
remained responsive to IGFs, cortisol, and growth 
hormone. 
Thus far, it has not been possible to directly test 
[ 14,151 the effects of native, physiologically occur- 
ring IGF carrier proteins on the interaction bet- 
ween IGF I and its receptors on bone cells. 
Synthesis of IGF carrier proteins by target cells 
suggests additional auto-/paracrine control 
mechanisms: bone cells may by hormonally con- 
trolled release of IGF carrier proteins determine 
the availability of IGFs within their own compart- 
ment (i) by regulating the amount of IGFs kept in 
the close extracellular spaces and (ii) by changing 
(either enhancing or inhibiting) the access of IGFs 
to their receptors on bone cells. 
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